Facebook-f X-twitter Linkedin-in Instagram Youtube

Landing Page

All Content

Why the Federal Reserve Is Holding Off on Interest Rate Cuts

While other central banks begin easing policy in response to slowing global growth, the Federal Reserve is holding firm. Concerns about inflation, unemployment, and the uncertain impact of U.S. trade...

Should Investors Rush to Gold EFTs?

As economic uncertainty, inflation fears, and trade tensions shake investor confidence, Gold ETFs are emerging as a reliable hedge and a strategic portfolio enhancer. Learn why now may be the...

Hyundai’s $21 Billion U.S. Investment: A Strategic Move in a Shifting Market

Hyundai Motor Group is committing $21 billion to expand its presence in the United States. This investment focuses on growing manufacturing capacity, strengthening supply chains, and adapting to changing trade...

U.S. Critical Mineral Push as National Emergency Declared

In a decisive move to reduce America's reliance on foreign mineral imports, President Donald Trump has invoked emergency powers to bolster domestic production of critical minerals....

The Quantum Revolution is Here

Quantum computing is on the verge of transforming industries, offering unprecedented computational power that could redefine fields ranging from materials science to AI...

Trade War Hits Pharma: U.S.-EU Dispute Threatens Drug Prices

The pharmaceutical industry is on high alert as U.S.-EU trade tensions threaten to put blockbuster drugs in the tariff crosshairs....

Invested in Chip Stocks? Note this Mineral Ban

China's export restrictions on gallium and germanium are shaking up global supply chains. As industries adapt, investors are closely watching the U.S. for opportunities in domestic suppliers with strong growth...

Exxon Mobil Enters the AI Power Race with a ‘Huge Advantage’

Oil and gas giant Exxon Mobil has its sights set on the surging energy market for AI-driven data centres, leveraging its expertise in carbon capture and energy infrastructure....

Novartis Bets Big on Cardiovascular Biotech With $3bn Anthos Deal

Swiss pharmaceutical giant Novartis has announced an agreement to acquire Anthos Therapeutics from Blackstone Life Sciences in a deal valued at up to $3.1 Billion. The deal includes a $925...

en_USEnglish
de_DEGerman en_USEnglish